Table 1. FDA-approved preparations of alpha1-proteinase inhibitor (human) at study time
Figure 1. Schematic trial design.
Table 2. Patient demographics
Table 3. Baseline characteristics
Figure 2. Non-inferiority. Trough circulating levels of mean (SD) A1PI from baseline to week 12.
Table 4. Non-inferiority; Trough circulating levels of antigenic and functional A1PI (average of weeks 7 to 12)
Table 5. Adverse events occurring in ≥ 10% of patients
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
